- Emerging Toxicology of Illicit Opioids: From Overdose Pathophysiology to Organ Injury and Medical Countermeasures
-
Stars at Night Ballroom B4‚ Convention Center
Chair: Satya Achanta, Duke University School of Medicine
Co-Chair: Devon Graham, Florida State University College of Medicine
Primary Endorser: Clinical and Translational Toxicology Specialty Section
Endorser(s): Comparative Toxicology, Pathology, and Veterinary Specialty Section
Endorser(s): Exposure Specialty Section
Illicit synthetic opioids, particularly fentanyl and its analogs, continue to drive an escalating public health crisis and are increasingly recognized as an emerging national security concern. Fentanyl and carfentanil are ultra-potent opioids with rapid central nervous system penetration that produce profound respiratory and cardiovascular depression. Recent surveillance data indicate a growing prevalence of polysubstance exposures, most notably fentanyl adulterated with xylazine, a veterinary a2-adrenergic receptor agonist not approved for human use. These emerging drug combinations are associated with rising overdose fatalities and severe multisystem injury, yet major gaps remain in our understanding of their toxicological mechanisms, long-term organ injury, and effective medical countermeasures.This Scientific Session will present complementary translational and preclinical investigations examining the cardiopulmonary toxicity of fentanyl and carfentanil alone or in combination with xylazine across multiple and incremental animal models. Studies using mouse aerosol exposure models demonstrate that inhaled fentanyl can directly injure pulmonary and cardiac tissues, producing acute lung inflammation, hypoxemia, and pulmonary edema, followed by chronic structural remodeling characterized by fibrosis, emphysematous airspace enlargement, and cardiomyocyte injury. These findings suggest that fentanyl exposure may contribute not only to acute overdose mortality but also to persistent cardiopulmonary damage independent of immediate lethality.Additional investigations using rat overdose models reveal that fentanyl induces acute lung injury, respiratory dysfunction, and systemic organ toxicity. Naloxone effectively reverses many life-threatening clinical signs associated with opioid overdose, including respiratory depression and hypoxemia. However, biomarker and histopathological analyses demonstrate persistent pulmonary and systemic injury despite opioid receptor antagonism. These findings highlight important limitations of current rescue strategies and underscore the need for improved therapeutic interventions.Expanding upon these mechanistic insights, large-animal swine models demonstrate that co-exposure to fentanyl and xylazine produces synergistic cardiopulmonary depression characterized by severe bradycardia, hypotension, arrhythmias, respiratory suppression, and cerebral hypoxia exceeding the toxicity observed with either drug alone. Pharmacologic studies indicate that combined treatment with naloxone and a2-adrenergic receptor antagonists, including atipamezole and yohimbine, can reverse acute cardiopulmonary depression, although re-narcotization remains a significant clinical challenge. The session will also highlight emerging medical countermeasure strategies, including the development of novel antibodies targeting ultra-potent opioids such as carfentanil, along with other pharmacological antidotes.Collectively, this session will highlight growing evidence that illicit opioid exposures represent a complex multisystem toxicological threat extending beyond respiratory depression to include acute and chronic cardiopulmonary injury, multiorgan toxicity, and significant challenges in medical countermeasure development. By integrating mechanistic insights, translational modeling approaches, and therapeutic evaluation strategies, including discussion of regulatory pathways for antidote development under the US Food and Drug Administration Animal Rule, this session aims to address critical knowledge gaps in illicit opioid toxicology and inform future research, clinical management, and public health preparedness.This topic is broadly relevant to the toxicology community, including clinical and translational toxicologists, comparative and mechanistic toxicologists, toxico-pathologists, exposure scientists, inhalation toxicologists, drug discovery toxicologists, and researchers developing in vitro or alternative models. It is also of strong interest to federal and regulatory agencies (e.g., DEA, US FDA, NIH, US EPA), as well as industry stakeholders engaged in the development of medical countermeasures.
IAT ITS Designation: Innovations in Toxicological Sciences (ITS)
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
